Medical Dermatology
From the Journals
Autologous stem-cell transplantation for scleroderma beats cyclophosphamide in long term
Hematopoietic toxicity should be weighed against the benefits of transplantation.
From the Journals
Pemphigus associated with higher risk of hematologic malignancies
Patients with pemphigus were twice as likely to have chronic leukemia and multiple myeloma.
Conference Coverage
Skin signs spotlight highest-risk SLE patients
GENEVA – “Those are the lupus patients who still die today.”
News
FDA approves Eskata for treatment of raised SKs
Topical solution should be used only in the office of a health care provider, not in the home.
News
FDA approves first therapy treatment for EGPA
Approval of using mepolizumab for EGPA was based on data from a 52-week clinical trial that compared it with placebo, according to the FDA.
Make the Diagnosis
Make the diagnosis - January 2018
A 32-year-old man presented with perioral erythematous to hypopigmented atrophic plaques with peripheral hyperpigmentation, what's the diagnosis...
Conference Coverage
MAVORIC: Mogamulizumab tops vorinostat in pretreated CTCL
ATLANTA – Mogamulizumab topped vorinostat in terms of overall response to treatment and on several quality of life scales
Conference Coverage
Novel oral orphan drug tames pemphigus
The Bruton tyrosine kinase inhibitor is also under study for other autoimmune diseases.
Conference Coverage
Nonadherence to lupus drugs may play a role in frequent hospitalization
SAN DIEGO – A higher risk for hospitalization also occurred among young, male, and African-American patients.
Conference Coverage
Blisibimod shows mixed results for lupus in phase 3 trial
SAN DIEGO – The drug did not meet its primary endpoint but was associated with steroid sparing, decreased urine protein, and improved biomarker...
Conference Coverage
Anabasum shows promise in treating skin-predominant dermatomyositis, systemic sclerosis
SAN DIEGO – The investigational drug met primary endpoints and showed good safety in two phase 2 studies.